Key Highlights

● Two Phase 3 DIAMOND trials of OCS-01 missed their primary endpoint on May 29, 2026.

● Resources shift to privosegtor for optic neuropathies and licaminlimab for dry eye.

● Cash and short-term financial Assets together totaled about CHF 228 million at June 30.

● Oculis raised CHF 47.8 million gross selling 2.25 million shares in an at-the-market program.

Oculis Holding AG (NASDAQ:OCS) is a clinical-stage ophthalmology company whose year changed course on May 29, 2026, when two Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema missed their primary endpoint. Chief executive Riad Sherif said the team was naturally disappointed, and management has since redirected attention to its other late-stage programs. With a third-quarter update still to come, investors may be weighing how credible that pivot looks and how long the cash could last, and what management says next about priorities and timelines.

Latest Company Context

OCS-01 was Oculis's most advanced asset in diabetic macular edema. The DIAMOND-1 and DIAMOND-2 trials enrolled more than 800 patients at 119 sites; the primary endpoint, change in best-corrected visual acuity at Week 52, was not met, nor was a key secondary endpoint on the proportion gaining at least 15 letters. The company reported reductions in retinal thickness versus vehicle and no unexpected safety findings, but said it does not currently plan an FDA filing in that indication.

Management said resources would shift to privosegtor, a neuroprotective candidate in the PIONEER program for optic neuropathies, and to licaminlimab, a topical anti-TNF-alpha in a registrational trial for dry eye disease. In the earlier May 11 first-quarter update, Sherif had spoken of strong execution momentum, which the subsequent readout complicated. The shares trade on Nasdaq under OCS, and no major US index membership was verified.

Key Business and Index Drivers

The half-year report to June 30, 2026 gives the financial picture. Net loss was CHF 10.0 million for the second quarter and CHF 38.8 million for six months, versus CHF 58.6 million in the prior-year half, with the latest figure including a CHF 4.1 million Fair Value gain on Warrant liabilities. Research and Development expense was CHF 29.3 million for six months, roughly flat, while general and administrative expense rose CHF 4.9 million to CHF 16.5 million, largely on share-based compensation.

Cash and equivalents were CHF 61.6 million and short-term financial assets CHF 166.7 million, together about CHF 228 million. The company raised CHF 47.8 million gross by selling 2.25 million shares under an at-the-market program. In May, management said cash supported operations into the second half of 2029, a statement made before the half-year spending and share sales.

What Investors Should Watch

Investors may watch the third-quarter results, for which a date was not confirmed in the sources reviewed, for updated cash, burn and any commentary on pipeline priorities. Licaminlimab topline data from the PREDICT-1 trial were guided in May for around year-end 2026, and any change to that timing could matter. Privosegtor's PIONEER-1 trial was in site activation with an FDA Special Protocol Assessment in place, so enrollment progress may become a recurring disclosure.

Management also noted that it found no Impairment tied to OCS-01. Further use of the at-the-market Facility could potentially dilute existing shareholders, while additional partnering or financing news may shape the runway. Analyst reaction after the DIAMOND readout included lower price targets, but forecasts vary and are opinions, not facts. Investors may also watch for conference presentations where management could expand on development plans, regulatory interactions and Capital allocation across the three remaining late-stage programs.

Setback Tests the Remaining Pipeline

Oculis has traded a failed diabetic macular edema program for a sharper focus on optic neuropathies and dry eye, backed by roughly CHF 228 million of liquid resources at mid-year. Management commentary frames the pipeline as intact, while the clinical record now carries a notable setback. Readers may wish to review the company's 6-K filings directly, and to treat any outlook on trials or financing as scenarios that depend on clinical and market outcomes.